Treatment for Valley Fever (Coccidioidomycosis)
Initial Management Based on Disease Severity
- For patients with mild to moderate symptoms who are otherwise healthy, antifungal therapy is generally not required as most infections are self-limited and resolve spontaneously 1
- Patient education about the disease course, expected symptoms, and when to seek further medical attention is essential for all patients 1
Indications for Antifungal Therapy
- Antifungal treatment should be initiated for patients with severe primary pulmonary disease with significant symptoms 1
Antifungal Treatment Options
- Fluconazole is the standard first-line drug of choice for most cases requiring treatment, with a typical dosage of 400 mg daily for mild-moderate disease 1
- Fluconazole is the standard first-line drug of choice for most cases requiring treatment, with a typical dosage of 800 mg daily for severe disease 1
- Itraconazole (200 mg twice daily) may be more effective for skeletal infections 1
- Liposomal amphotericin B is recommended for critically ill patients 1
- Liposomal amphotericin B is recommended for patients with rapidly progressive disease 2
- Liposomal amphotericin B is recommended for patients who fail to respond to azole therapy 1
Special Considerations
- Surgical intervention should be considered for persistent symptomatic cavities that have been present for more than 2 years or when symptoms recur after stopping antifungal treatment 1
Common Pitfalls and Caveats
- Avoid unnecessary antifungal treatment in immunocompetent patients with mild disease, as this can lead to adverse effects without clinical benefit 1
Monitoring During Treatment
- Clinical parameters should be monitored regularly to assess treatment response 3